Dr. Schadendorf Discusses Sequencing Agents in Melanoma

Dirk Schadendorf, MD
Published: Wednesday, Dec 20, 2017



Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.
SELECTED
LANGUAGE


Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x